Statin use decreases inflammation and reduces cardiovascular events, and may be useful among persons with HIV, who have increased risk of cardiovascular (CV) events. Other benefits are unclear; some studies suggest that statins benefit physical function despite myalgias as a common side effect. We compared age-associated changes in physical function among men with or without statin use in the Multicenter AIDS Cohort Study.
Men 40-75 years old with ≥2 measures of gait speed or grip strength (baseline=2007) were included. Consistent statin use was defined as use at ≥80% of visits. Gait speed was measured on a 4-m course and grip strength by handheld dynamometer. Generalized estimating equations included an interaction term for statin group and age; models were further adjusted for demographics, HIV status, and CV risk factors.
Among 2021 men, median age was 52 (IQR 46,58) years; 68% were white, 27% black non-Hispanic, and 60% were overweight/obese. 636 were consistent (51% with HIV), 398 intermittent (61% HIV), and 987 never statin users (49% HIV). Duration of follow-up was 8.5 years (IQR 4.4, 10.4). Baseline gait speed was 1.12 m/sec (IQR 0.99, 1.25) and grip strength 38 kg (IQR 32, 44). Unadjusted changes in gait and grip are shown in the Figure. After adjusting for baseline, demographics, and CV risk factors, gait speed declined at -0.0028 m/s per year of age among all men, with no significant difference in gait speed decline among consistent vs never users (-0.0002 [-0.002, 0.0016], p=0.87). Intermittent users had a steeper gait speed decline over time vs never users (-0.0028 [-0.0048, -0.0007], p=0.007). Similar effects were seen with statin group and grip strength, with similar strength changes over time among consistent vs never users (-0.062 [-0.17, 0.041], p=0.24), but tended to decline more among intermittent users (-0.109 [-0.22, 0.007], p=0.07). HIV serostatus was not associated with gait speed (-0.002 [-0.0162, 0.0123) or grip strength (-0.212 [-0.997, 0.574]; p≥0.60). Although pain was strongly associated with gait and grip decline, severe baseline pain did not confound the association between statin use and physical function.
Consistent statin use had no apparent effect on declines in gait and grip strength, suggesting no statin-associated impairments in physical function in this population.